This first-in-human study investigated the therapeutic use of samalizumab as a CD200 immune checkpoint inhibitor in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.